
Meet the physicians, scientists, and business and political leaders whose work is transforming health care right now

Meet the physicians, scientists, and business and political leaders whose work is transforming health care right now

The U.S. Department of Health and Human Services (HHS) is doing everything from sharing more data to cultivating entrepreneurial talent and engaging in partnerships in order to support medical device innovators, the department’s CTO Ed Simcox told than 100 industry insiders in the Twin Cities today.

VLP Therapeutics announced the issuance of US Patent 10,098,943 titled, “Flavivirus virus-like particle” on October 16, 2018. This patent supports VLP Therapeutics’ Native Virus Modification virus-like particle platform on which the Company’s dengue vaccine is based and which could form the basis for other flavivirus vaccines. The patent relates to a virus-like particle vaccine comprising flavivirus structural proteins to prevent or treat flavivirus infection. Flavivirus includes dengue virus, West Nile virus, Japanese encephalitis, hepatitis C virus, and Zika virus.

Rexahn Pharmaceuticals, Inc. (NYSE American: RNN) today announced it has entered into definitive agreements with institutional investors to purchase approximately 5.77 million shares of its common stock and warrants exercisable for up to approximately 5.77 million shares of its common stock for gross proceeds of approximately $7.5 million. The shares and warrants are being sold in units, each consisting of one share of common stock and a warrant to purchase one share of common stock, at an offering price of $1.30 per unit. The warrants will be exercisable six months following the date of issuance, will expire on the fifth anniversary of the initial exercise date and will have an exercise price of $1.67 per share. The closing of the offering is expected to take place on or about October 19, 2018, subject to the satisfaction of customary closing conditions.
Top 3 by 2023
State of the BioHealth Capital Region’s EcoSystem
Rich Bendis
President & CEO, BioHealth Innovation Inc.

Pharma hasn’t traditionally been known as a sector that welcomed innovation from the outside. But now companies are putting “not invented here” bias aside as they seek to widen their aperture for innovation.
![]()
Based in Rockville, MD
Management Recruiters – Mid Hudson Valley is an executive search firm focused solely in serving the nonprofit sector. We have a national practice and the large majority of our placements are executive leadership and senior fundraising professionals.
Our client is Montgomery College, a community college of more than 60,000 students in Montgomery County, MD. The College is seeking a Vice President for Development and Alumni Relations who also serves as the Executive Director of the Montgomery College Foundation. The position is a College employee.

The Cybersecurity Association of Maryland, Inc. (CAMI) and Universities at Shady Grove invite you to attend their November 9 & 10 Maryland Cybersecurity Career & Education Fair.
Maryland is at the forefront of our nation’s rapidly growing cyber market and opportunities abound for professionals in our region—both those who are new to the field, and long-time members of the industry. Join us at the Universities at Shady Grove for two dynamic days that put on display why Maryland is where cyber works. Friday will feature a career and education fair, connecting cybersecurity job seekers with opportunities across the state of Maryland. Those looking to expand their cybersecurity competency can also connect on-site with Maryland education and training resource. On Saturday, cyber warriors of high school through undergraduate skill levels are invited to compete in our “Catch the Phish: An AI Capture the Flag Event” cyber challenge.

MaxCyte, the global cell-based medicines and life sciences company, announced today that the first patient has been dosed in its Phase I dose-escalation clinical trial in the United States with the Company’s lead wholly-owned chimeric antigen receptor (CAR) therapeutic candidate, MCY-M11. The study is designed to evaluate MCY-M11, a mesothelin targeting CAR, in individuals with relapsed/refractory ovarian cancer and peritoneal mesothelioma.

More than 300 representatives of companies from throughout the BioHealth Capital Region took over BowlMore Gaithersburg last Thursday for a fun evening of networking. The 5th annual BioBowl cohosted by MedImmune and BioHealth Innovation included teams from Baltimore and DC to Montgomery and Frederick counties. Qiagen took home the First Place prize and the Women in Bio event were recognized for their efforts with a Rubber Chicken Award.